Research Funding: Looking Beyond NIH

Dean’s Leadership Retreat

UHealth UNIVERSITY OF MIAMI HEALTH SYSTEM
MILLER SCHOOL of MEDICINE
Saturday, April 26, 2014

8:00 – 8:30  Continental Breakfast and Networking

8:30 – 8:40  Why We Chose the Topic
Omaida C. Velazquez, M.D., F.A.C.S.
Executive Dean for Research, Research Education and Innovative Medicine

8:40 – 8:45  Revelations, Cures and Clinical Innovations
Video: The Impact of UMMSOM Research

8:45 – 9:05  Funding our Key Scientific Areas
Pascal J. Goldschmidt, M.D.
Senior VP for Medical Affairs and Dean

9:05 – 9:20  Philanthropy at the UMMSOM
Mary Ann Sprinkle
Associate Vice President of Medical Development and Alumni Relations

9:20 – 10:10  Philanthropy – the new way to fund science research?
Inge Reichenbach
Reichenbach Consulting LLC
Prior: VP, Development at Yale University and Cornell University

10:10 – 10:30  Break
10:30 – 11:00 A Successful Partnership
Richard Postrel
Founder of the Miami-based company Signature Systems, LLC
Inventor of Swilt Exchange

Stephan Züchner, M.D., Ph.D.
Interim Chair and Professor of the Dr. John T. Macdonald Foundation
Department of Human Genetics and Professor of Neurology

11:00 – 11:20 Successful Partnerships
Joshua Hare, M.D.
Chief Sciences Officer, Senior Associate Dean for Experimental and Cellular Therapeutics, Director of the Interdisciplinary Stem Cell Institute (ISCI), and Louis Lemberg Professor of Medicine

11:20 – 11:50 Exercise: Planning your Research Funding Strategy

11:50 – 11:55 Philanthropists for Biomedical Science
Video: Biomedical Research and Philanthropy can Change the World

11:55 – 12:00 Wrap up
Omaida Velazquez, M.D., F.A.C.S.
Explore New Funding Sources

PIVOT
http://pivot.cos.com/funding/results

Pivot combines the most comprehensive, editorially maintained database of funding opportunities worth an estimated $33 billion with a database of 3 million pre-populated scholar profiles, drawing from Community of Scholars and Community of Science profiles.
1. Enter your research interests in the keyword search box
2. Use the choices in the left column to refine your search

SPIN
http://infoedglobal.com/

SPIN offers over 40,000 opportunities from more than 10,000 global sponsors. It is intuitive to use and engages powerful data mining.
1. Click on "SPIN" from top line "CLIENT LOGIN TO:"
2. Enter your research interests in the search field
3. You can refine your search by starting with "ADVANCED" in "Search mode" on the upper right
4. Build your custom criteria
Explore New Funding Sources

Foundation Directory
https://catalog.library.miami.edu/patroninfo~S11

A service of the Foundation Center, a leading source of philanthropy worldwide – a unique databases of information on more than 108,000 foundations, corporate donors, and grantmaking public charities in the U.S. and over 3 million of their recent grants.

1. Log in using your CaneID logon
2. Enter “foundation directory” as the keyword and click “Search”
3. Connect to “Foundation Directory Online” via the hyperlink
4. Choose “Search Grantmakers” from the menu on the top right
5. Enter your criteria or choose from “view index” for selected fields and choose “Search”
**Explore New Funding Sources**

**Chronicle of Philanthropy**
http://philanthropy.com/factfile/gifts/1?DonorDisplayName_cu=&Category=Medical+research&GiftRecipients_RecipOrgDateline_c=&GiftRecipients_RecipStateFull=any&GiftDonors_SourceWealth_cu=&GiftDonors_aStateFull=Florida&GiftYear=any

The *Chronicle of Philanthropy* is the No. 1 news source, in print and online, for people involved in the philanthropic enterprise. For more than 20 years, *The Chronicle* has been connecting the nonprofit world with news, jobs, and ideas. This database displays gifts that have already been made – you can use it to find potential donors in your field of interest, not active funding opportunities.

1. Enter criteria into any or all of the search criteria

**Forbes 400 List**
http://www.forbes.com/forbes-400/list/

This is the list of the 400 richest people in America including their net worth and residence. There are no funding opportunities here, just potential philanthropists – maybe someone you know.

1. Click “Continue to Site” in the upper right hand corner
2. Use the filters on the left to narrow your search
Pascal J. Goldschmidt, M.D.

Pascal J. Goldschmidt, M.D., an internationally renowned cardiologist and cardiovascular researcher, is Senior Vice President for Medical Affairs and Dean of the University of Miami Leonard M. Miller School of Medicine. He also serves as Chief Executive Officer of the University of Miami Health System (UHealth), which includes three hospitals and more than two dozen outpatient facilities in Miami-Dade, Broward, Palm Beach, Monroe and Collier counties, with more than 1,200 physicians and 8,000 staff. Since his arrival in April 2006, Dean Goldschmidt has overseen tremendous growth on the medical campus in Miami, with the November 2007 purchase of Cedars Medical Center, which is now University of Miami Hospital, the flagship hospital of UHealth. He also established the first allopathic internal medicine residency training program in Palm Beach County.

New global health clinical and research initiatives include the Global Institute for Community Health and Development and the International Medicine Institute. It was through the Global Institute for Community Health and Development that Dean Goldschmidt was able to launch and oversee the medical relief effort in Haiti after the January 2010 earthquake. A team of Miller School physicians, nurses and staff was the first to arrive in Port-au-Prince, and within nine days of the earthquake the University of Miami Hospital in Haiti was open and treating patients. The research enterprise has also grown significantly since 2006 with the creation of the John P. Hussman Institute for Human Genomics, the Dr. John T. Macdonald Foundation Biomedical Nanotechnology Institute at UM (BioNIUM), and the Interdisciplinary Stem Cell Institute. All three institutes are headed by world-renowned researchers. In October 2008, Dr. Goldschmidt received the inaugural Jay and Jeannie Schottenstein Prize in Cardiovascular Sciences from the Ohio State University Heart and Vascular Center. The prize is awarded biennially to an international leader in the clinical sciences of cardiovascular medicine, cardiothoracic surgery, or the basic sciences of molecular or cellular cardiology.

Dr. Goldschmidt, whose research applies genomics and cell therapy to the prevention, diagnosis and treatment of coronary artery disease, was previously chairman of the Department of Medicine at Duke University Medical Center. Before taking the chairman’s role, he served as chief of Duke’s Division of Cardiology.
Pascal J. Goldschmidt, M.D., continued

Before joining the Duke faculty in 2000, he was director of cardiology at The Ohio State University College of Medicine and Public Health, where he built the Heart and Lung Research Institute and launched a heart hospital. A native of Belgium, Dr. Goldschmidt received his medical degree from the Université Libre de Bruxelles and completed residency and fellowship training in Brussels at Erasme Academic Hospital and in the United States at Union Memorial Hospital and The Johns Hopkins University. Following his training at Hopkins, he served as an assistant, then associate professor in the university's Division of Cardiology in the Department of Medicine, Department of Cell Biology and Anatomy and Department of Pathology until 1997.

Mary Ann Sprinkle

A native of Virginia, Mary Ann Sprinkle has been in fundraising for thirty years. Currently, she serves as Associate Vice President for Medical Development & Alumni Relations at the University of Miami Miller School of Medicine. Ms. Sprinkle is responsible for overseeing the MSOM advancement teams that are charged with raising $1B for Momentum2: The Breakthrough Campaign for the University of Miami – with an overall University campaign goal of $1.6B. Prior to her current role, Sprinkle was Assistant Vice President for Medical Development & Alumni Relations for the MSOM. She served as Director of Development for the National Parkinson Foundation as well as Managing Director of Development for Florida Grand Opera. While in the state of Oregon, she was Director of Development for Willamette University College of Law and Director of Development for Willamette University in addition to Director of Development for Portland Opera.

Among her professional and personal affiliations, Ms. Sprinkle has been active with the Council for Advancement and Support of Education (CASE), serving in several regional and national leadership roles in the past, and with Stephens College, her undergraduate alma mater. Locally, she serves as secretary of the non-profit board, United HomeCare, Inc., the largest provider of home health care in Miami-Dade County. In addition to graduating summa cum laude from Stephens College, with a B.A. in Psychology, she has a M.S. in Counseling from the University of Oregon.
Joshua Hare, M.D.

Joshua Hare, M.D. is Chief Sciences Officer, Senior Associate Dean for Experimental and Cellular Therapeutics, Director of the Interdisciplinary Stem Cell Institute (ISCI), and Louis Lemberg Professor of Medicine at the University of Miami Miller School of Medicine. Dr. Hare is an expert in cardiovascular medicine and specializes in heart failure, myocardial infarction, inflammatory diseases of the heart, and heart transplantation. He is an internationally acknowledged pioneer in the field of stem cell therapeutics for human heart disease, currently seeing and evaluating patients from all over the world for this new experimental therapy.

Dr. Hare is the founding director of the Interdisciplinary Stem Cell Institute, an Institute devoted to basic scientific and translational work in the field of stem cell therapy and regenerative medicine. The Institute houses 50 faculty members and 15 independent research groups.

Dr. Hare led the first randomized allogeneic mesenchymal stem cell (MSC) clinical trial for patients with myocardial infarction and is principal investigator of multiple other trials for heart failure and cardiovascular disease. Under his leadership, ISCI now has active programs in cancer biology, cardiology, neonatology, skin diseases, bone diseases, neurologic diseases, ophthalmology, and a program devoted to the ethics of stem cell therapy.

Dr. Hare has published more than 250 original research articles, editorials, and review articles, and is the recipient of seven grants from the National Institutes of Health. He holds 6 FDA Investigational New Drug applications for cell-based therapy in patients with heart disease, including the first in the United States for Idiopathic Pulmonary Fibrosis and the first for Aging Frailty. He is the recipient of four active NIH R01’s and is the PI of the UM National Heart Lung and Blood Institute Cardiac Cell Therapy Trial Network (CCTRN) center; together these awards fund ~$2M in basic and translational research annually.
Joshua Hare, M.D., continued

Under Dr. Hare’s leadership, ISCI has been awarded $10M from the Cornellius Starr Foundation. Dr. Hare recently completed a term as chair of the Cardiac Contractility and Heart Failure study section of the National Institute of Health (NIH), chairs the Stem Cell Working Group of the American Heart Association (AHA), and is the incoming Chair of the AHA Easic Cardiovascular Science Council.

Educated at the University of Pennsylvania (1984), Johns Hopkins University School of Medicine (1988), The Brigham and Women’s Hospital (1994), and Harvard Medical School, Dr. Hare spent 12 years on the faculty at Johns Hopkins University School of Medicine where he rose to the rank of Professor of Medicine and Biomedical Engineering, and Director of the Cardiac Transplant and Heart Failure program in 2004 before joining the faculty at the University of Miami Miller School of Medicine in 2007. Dr. Hare is an elected member of the American Association of Physicians (2011) and the Association of University Cardiologists (2007). Dr. Hare is inventor of 10 (three issued) United States patents, and his research discoveries have led to the founding of three biotechnology companies.
Omaida C. Velazquez, M.D., F.A.C.S

Omaida C. Velazquez, M.D., F.A.C.S., professor of surgery and David Kimmelman Endowed Chair in Vascular and Endovascular Surgery is Chief of the Division of Vascular and Endovascular Surgery at the University of Miami Miller School of Medicine. She is a member of the American Surgical Association (ASA), an elite group composed of the nation’s most prominent surgeons from the country’s leading academic medical institutions.

Dr. Velazquez’s current research focuses on further understanding and advancing new treatments for lower extremity arterial occlusive disease and diabetes-related wound healing defects. Dr. Velazquez is the Principal Investigator of a NIH-funded basic science laboratory that investigates endothelial cell biology, angiogenesis, and vasculogenesis. Her clinical expertise focuses on endovascular and other minimally invasive approaches in the surgical treatment of vascular diseases. She has extensive expertise in both open and endovascular repair of abdominal aortic aneurysms, open and endovascular treatments for carotid, mesenteric, and renal stenosis and novel treatments for critical limb ischemia.

In addition to her roles as a surgeon and a scientist, Dr. Velazquez serves as the Executive Dean of Research, Research Education and Innovative Medicine for the Miller School of Medicine. Under her leadership, investigators across campus have seen the clinical research infrastructure enhanced, administrative processes demystified and interdepartmental communications increased. Dr. Velazquez obtained her B.S. from Stevens Institute of Technology in 1987 and obtained M.D. degree from the University of Medicine and Dentistry of New Jersey, New Jersey Medical School graduating Valedictorian in her class of 1991. She completed her postgraduate training in General and Vascular Surgery at the University of Pennsylvania. In addition to her clinical training, she pursued additional years in research and was the recipient of the 1997 Jonathan E. Rhoads Research Award. She received the von Liebig Foundation Award for Excellence in Vascular Surgical Research (2001), the University of Pennsylvania Center of Excellence Faculty Scholar Award (2002), and the Joel J. Reslyn Faculty Research Award (2003). Before joining the Miller School of Medicine, she served on the faculty at the University of Pennsylvania for eight years and became an Associate Professor with tenure.
Inge T. Reichenbach gained her extensive fundraising experience at Cornell University and Yale University, before establishing her own consulting firm in 2012. Her leadership experience at Cornell and Yale spans 17 years as Vice President, the chief fundraising position at both institutions, reporting directly to the President.

At Cornell, she led the university's first billion dollar campaign to a successful $1.5 billion conclusion in 1995, exceeding the goal by $250 million. At Yale, she led the Yale tomorrow campaign to $3.9 billion in 2011, $900 million over its initial goal and during one of the worst global financial crises. In addition to the planning and execution of these two comprehensive campaigns, Ms. Reichenbach was instrumental in developing and personally soliciting eight-and nine-figure gifts, establishing new fundraising programs, and developing international giving. Over the years she has managed organizational build-up and downsizing, and, while focusing on professional development for staff and maintaining morale through challenging times, significantly increased giving between campaigns. After the Cornell Campaign, the average monthly total of new gifts and commitments rose by 84%.

Ms. Reichenbach is a frequent speaker at international conferences, a writer on fundraising and philanthropy and serves on several international committees. Her consulting focus is on strategic planning of institutional fundraising campaigns, program development and a special emphasis on developing transformative gifts. Her client list since 2012 include the American University of Beirut, MIT, Dartmouth, The Broad Institute, the Max Planck Florida Institute, Rensselaer Polytechnic Institute, Amherst College, Smith College, Shalem College in Jerusalem and the American School of Classical Studies in Athens.

*Photo by Jason Grow Photography*
Stephan Züchner, M.D., Ph.D.

Stephan Züchner, M.D., Ph.D. is the Interim Chair and Professor of the Dr. John T. Macdonald Foundation Department of Human Genetics and Professor of Neurology at the Miller School of Medicine. He is also a co-founder and President of the Board of ViaGenetics Inc., a Miami start-up that is seeking to redefine and accelerate genome research and its future applications.

Dr. Züchner is a pioneer in developing and applying next-generation sequencing based approaches to medicine. His team has developed the first and one of the most widely used web-based genome analysis and sharing platforms in the world (GEM.app). GEM.app is being used by large and small institutions in 34 countries and has helped to identify nearly 60 novel familial disease genes in the past 18 months.

Other innovations include the first direct deep mitochondrial DNA sequencing, the first genome-based genetic forward screen in drosophila, and new implementations of non-relational distributed databasing of genome scale data.

As a trained neurologist/neuropathologist and molecular geneticist his research focus is on disorders of the nervous system where he identified familial and so-called ‘complex’ disease genes for dozens of disorders, including axonopathies, obsessive compulsive disorder, Alzheimer and Parkinson disease. His discoveries have led to clinical genetic tests that are used by tens of thousands of patients worldwide every year. His work is published in the most impactful journals in the field and as a PI he currently manages over $10M in research grants from NIH and foundations.
Richard Postrel

Richard Postrel is the CEO of ViaGenetics, a revolutionary "profit with a purpose" bio-technology, data-aggregation and research company. The firm operates and sponsors a global information-sharing network with nearly three hundred of the world's top universities and researchers. He is responsible for strategic planning and intellectual property development.

Mr. Postrel is also CEO of Signature Systems LLC, an intellectual property development firm. He specializes in process and method patents. Signature System's patent portfolio currently consists of 111 issued and pending patents in payment technology, financial services, information exchange, central server systems and internet technologies.

Previously, Mr. Postrel designed and built the world's first dynamic foreign exchange system, the first electronic options trading system and the first internet-based point-of-sale device. He was selected as one of the leading innovators by the American National Academy of Sciences.
RIM Services

Research, Research Education and Innovative Medicine provides services for investigators, including:

- Clinical Research Center
- Core Facilities and Shared Resources
- Clinical Research Operations and Regulatory Support
- Emergency Preparedness
- Freezer Facility
- Graduate and Postdoctoral Services
- Internal Awards Program
- Medical Research Enterprise Program Support Unit, MEDReps
- Pre-Award Enhancement Project